Thermo Fisher (TMO) is a publicly traded Healthcare sector company. As of May 20, 2026, TMO trades at $449.99 with a market cap of $164.26B and a P/E ratio of 24.62. TMO moved +0.93% today. Year to date, TMO is -24.42%; over the trailing twelve months it is +8.19%. Its 52-week range spans $385.46 to $643.99. Analyst consensus is strong buy with an average price target of $611.60. Rallies surfaces TMO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Thermo Fisher Q1 Revenue Hits $11.01B, EPS Beats Estimates, Flags Inflation Risk: Thermo Fisher reported Q1 adjusted EPS of $5.44 beating consensus by $0.20, while GAAP EPS of $4.43 missed estimates, and revenue reached $11.01 billion versus $10.86 billion forecasts. The company cautioned that Middle East tensions present a modest inflation risk to supply chains and highlighted a debt-to-equity ratio of 0.83.
| Metric | Value |
|---|---|
| Price | $449.99 |
| Market Cap | $164.26B |
| P/E Ratio | 24.62 |
| EPS | $18.22 |
| Dividend Yield | 0.47% |
| 52-Week High | $643.99 |
| 52-Week Low | $385.46 |
| Volume | 2.42M |
| Avg Volume | 0 |
| Revenue (TTM) | $45.20B |
| Net Income | $6.87B |
| Gross Margin | 0.00% |
17 analysts cover TMO: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $611.60.